Topic Hub
6 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 6 of 6 clinical reviews.
Low-dose naltrexone (LDN) is not FDA-approved at doses below 50 mg. Learn how 503A compounding pharmacies legally prepare LDN, current regulatory status, and the clinical evidence behind off-label prescribing.
Read clinical reviewA clinical review of Low-Dose Naltrexone (LDN) safety signals in the FDA Adverse Event Reporting System (FAERS), including reported adverse events, label context, and what prescribers should monitor.
Read clinical reviewA clinical review of low-dose naltrexone (LDN) regulatory status worldwide, including FDA-approved naltrexone labeling, 503A compounding pharmacy rules, and off-label prescribing frameworks in the US, EU, UK, and Australia.
Read clinical reviewA clinical review of low-dose naltrexone (LDN) regulatory status from 2020 through 2026, covering FDA-approved labeling for naltrexone 50 mg, compounding pharmacy oversight under 503A/503B, and emerging safety and efficacy data.
Read clinical reviewA clinical and regulatory review of LDN's off-label legal status, compounding pharmacy oversight, patent barriers, and the FDA approval gap that keeps low-dose naltrexone without a dedicated label.
Read clinical reviewCurrent FDA regulatory status of low-dose naltrexone (LDN), ongoing clinical trials, compounding pharmacy access, and what next-generation formulations may change for patients.
Read clinical review